SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences Holdings LTD (SCS), have signed an exclusive agreement to manufacture and market novel patent-protected embryonic stem (ES) cell media for the research market. Under the terms of this agreement, SCS will transfer the patented technology and expertise to Chemicon to allow it to manufacture a fully formulated cell culture media that Chemicon will exclusively market worldwide. This novel media has substantial improvements over animal-serum based media formulations. The availability of this new serum-free, ready-to-use media offers advantages in convenience and reproducibility, eliminating lot-to-lot variations inherent with the use of animal serum. Specific formulations will be provided for different aspects of passaging and clonal selection of mammalian ES cells. The flagship ready-to-use formulation will contain Chemicon's proprietary LIF as well as proprietary molecules patented by SCS. SCS has been active in the stem cell research arena since 1994, principally focused on technologies to grow, differentiate, select and purify embryonic stem cells. SCS has a substantial portfolio of patents and patent applications within these areas, and intends to develop SC-based therapies. "Chemicon is excited to add these new ES cell culture media formulations to our portfolio of innovative reagents and technologies for the global stem cell research community," said Jeffrey D. Linton, President of Chemicon. "These new media formulations will aid researchers in the passaging and selection of mammalian ES cell lines. These new products will broaden the solutions already being provided to thousands of ES cell researchers worldwide via our LIF and ESGRO(R) product lines. In addition, we look forward to furthering our collaboration with Stem Cell Sciences to co-develop and market additional innovative ES cell products." "We are pleased to enter this agreement with a well-established stem cell research solutions provider such as Chemicon," said Peter Mountford, CEO of Stem Cell Sciences. "Chemicon is well positioned in the stem cell arena to both manufacture and provide the serum-free, fully formulated ES cell media formulations we have developed to researchers in the field of stem cell research and regenerative medicine." Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA. For more information, please visit our website: www.chemicon.com Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com About Stem Cell Sciences Stem Cell Sciences has been a leading company in the stem cell research arena since 1994, focused on technologies to grow, differentiate, select and purify embryonic stem cells. The SCS group has headquarters in Edinburgh, UK and laboratories in Melbourne, Australia and Kobe, Japan. It is expanding operations from 2006 to Cambridge UK and the USA. The new UK site in Cambridge will focus on automation of cell based drug discovery assays for the pharmaceutical industry. The US expansion will initially be based on licensing opportunities of key SCS technologies, including Stem Cell Selection and novel Neural Stem cells reported in August this year. Stem Cell Sciences plc was listed on the London AIM in July 2005. For more information, please visit our website: www.stemcellsciences.com This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release. Serologicals is a registered trademark of Serologicals Investment Company.